Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Huimin Qi

Showing results (61-70 of 63) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 63 results.
Peerj|February 2, 2026
The role of ASIC2 in glioma progression: implications for prognosis and therapeutic targetingWenxiu Tian, Yu Wang, Zhenming Wang, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|May 14, 2024
miR-4645-3p attenuates podocyte injury and mitochondrial dysfunction in diabetic kidney disease by targeting Cdk5Yue Zhang, Shunjie Xia, Xiaoxi Tian, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|March 14, 2024
Tangshen formula targets the gut microbiota to treat non-alcoholic fatty liver disease in HFD mice: A 16S rRNA and non-targeted metabolomics analysesShaopeng Wang, Xin Li, Bo Zhang, et al.
Pageof 7

Showing results (61-70 of 63) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 63 results.
Peerj|February 2, 2026
The role of ASIC2 in glioma progression: implications for prognosis and therapeutic targetingWenxiu Tian, Yu Wang, Zhenming Wang, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|May 14, 2024
miR-4645-3p attenuates podocyte injury and mitochondrial dysfunction in diabetic kidney disease by targeting Cdk5Yue Zhang, Shunjie Xia, Xiaoxi Tian, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|March 14, 2024
Tangshen formula targets the gut microbiota to treat non-alcoholic fatty liver disease in HFD mice: A 16S rRNA and non-targeted metabolomics analysesShaopeng Wang, Xin Li, Bo Zhang, et al.
Pageof 7